Exact Sciences stock closed at $36.47 Wednesday, up $3.82. The company’s shares have increased 449 percent during the past year.
The company’s completed test volume also grew year-over-year by 150 percent, according to the report.
More articles on supply chain:
Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health’s medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump’s drug pricing plans: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
